Table 3. Medication-Safety and Medication-Management Assessments in the Intervention and Control Arms of a Cluster-Randomized Controlled Trial of a Computerized Antithrombotic Risk Assessment Tool for General Practitioners in New South Wales, Australia^a .

Assessment	All Patients (N = 393)	Intervention Arm (n = 206)	Control Arm (n = 187)	P Valueb
Medication safety
Patient allergic to warfarin and aspirin	8 (2.0)	6 (2.9)	2 (1.1)	.22
Adverse reaction to antithrombotics	15 (3.8)	9 (4.4)	6 (3.2)	.52
Taking medication that interacts with warfarin	1 (0.3)	1 (0.5)	0 (0.0)	.73
Patient has declined antithrombotics	5 (1.3)	4 (1.9)	1 (0.5)	.38
Patient has contraindication to antithrombotics	11 (2.8)	5 (2.4)	6 (3.2)	.76
Patient has failed antithrombotics	10 (2.5)	6 (2.9)	4 (2.1)	.75
Patient received education about antithrombotics	380 (96.7)	198 (50.4)	182 (47.9)	.58
Medication management
Patient taking ≥4 medications	371 (94.4)	195 (94.7)	176 (94.1)	.83
Patient is not compliant with medication	22 (5.6)	8 (3.9)	14 (7.5)	.13
Patient needs assistance for medication management	161 (41.0)	83 (40.3)	78 (41.7)	.84
Difficulty accessing medical care	3 (0.8)	1 (0.5)	2 (1.1)	.61
Patient in residential care facility	4 (1.0)	2 (1.0)	2 (1.1)	>.99
Cognitive impairment	18 (4.6)	8 (3.9)	10 (5.3)	.63
Vision impairment	24 (6.1)	15 (7.3)	9 (4.8)	.40
Hearing impairment	34 (8.7)	18 (8.7)	16 (8.6)	>.99
Language/communication barrier	4 (1.0)	2 (1.0)	2 (1.1)	>.99
Mobility disorder	17 (4.3)	9 (4.4)	8 (4.3)	>.99
Functional impairment	63 (16.0)	26 (12.6)	37 (19.8)	.06

^a All values are number (percentage in subgroup) unless otherwise indicated.

^b P value for difference between intervention arm and control arm determined by Pearson χ² test.